We are live on ! Find out more
KIN

Kindred Biosciences, Inc.
KIN

Delisted

KIN was delisted on the 27th of August, 2021.

66 hedge funds and large institutions have $145M invested in Kindred Biosciences, Inc. in 2017 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 20 increasing their positions, 10 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

180% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 10

100% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 10

46% more call options, than puts

Call options by funds: $35K | Put options by funds: $24K

42% more capital invested

Capital invested by funds: $101M → $145M (+$43M)

38% more funds holding

Funds holding: 4866 (+18)

Holders
66
Holders Change
+18
Holders Change %
+37.5%
% of All Funds
1.65%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
28
Increased
20
Reduced
10
Closed
10
Calls
$35K
Puts
$24K
Net Calls
+$11K
Net Calls Change
+$107K
Name Holding Trade Value Shares
Change
Change in
Stake
Bank of Montreal
76
Bank of Montreal
Ontario, Canada
+$265 +37 +1,233%

KIN Hedge Fund Activity: Q2 2017 in Review

66 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Kindred Biosciences, Inc. (KIN) for Q2 2017, worth a combined $145M — up 42% from $101M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new KIN positions and 10 closed out — a net gain of 18 holders — while 20 added to existing stakes and 10 trimmed.

The largest buyer was BlackRock, adding an estimated $6.07M. The largest seller was Ariel Investments, cutting an estimated $7.28M.

  • 66 institutional investors held Kindred Biosciences, Inc. (KIN) as of Q2 2017, up from 48 in Q1 2017.
  • Funds reported $145M of Kindred Biosciences, Inc. stock for Q2 2017, up 42% quarter-over-quarter.
  • 28 funds opened new Kindred Biosciences, Inc. positions in Q2 2017 and 10 closed out, a net change of +18 holders.
  • The largest Kindred Biosciences, Inc. buyer in Q2 2017 was BlackRock, an estimated $6.07M added.
  • The largest Kindred Biosciences, Inc. seller in Q2 2017 was Ariel Investments, an estimated $7.28M sold.

Based on aggregated 13F filings for Q2 2017.